After hanging out the for sale sign and filing for bankruptcy earlier this year, the genetic testing provider Invitae has found a new home for its portfolio at Labcorp. The two companies announced ...

Bull case: Invitae has launched a plan to reach positive cash flow as soon as possible. Any progress could drive share gains. Bear case: Invitae comes with too much risk in an uncertain market. Could ...

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and Drug ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the fourth quarter and full year ended December 31, 2015. The company met its volume ...

Invitae will take part in a massive restructuring that will see it lay off more than 1,000 employees, exit some of its under-performing businesses, and reduce the more than 100 countries it serves to ...

Invitae’s revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability. Invitae shares have dropped more than ...